|
|
Overview and Purpose
The New Challenges in Treating GIST: Which Target, What
Agent, How Much, and When to Treat symposium
is intended to address new challenges that have arisen in the treatment
of GIST and to discuss the most effective
therapeutic strategies for managing the disease. Participants will
learn the rationale for using kinase inhibitors in the
adjuvant and neoadjuvant settings based on an understanding of
the molecular biology underlying the pathogenesis
of GIST. In addition, the importance of a multimodality team approach
utilizing expert skills of surgical oncologists,
medical oncologists, and radiologists to determine the best treatment
path for each patient will be discussed.
Optimal dose and duration of kinase therapy as well as novel alternatives
for TKI-resistant advanced disease will be
presented. Finally, interactive cases and moderated panel discussions
will attempt to answer questions concerning
standard criteria for a tumor response as well as treatment strategies
for localized GIST.
|
Target Audience
|
This educational program is directed toward medical oncologists,
surgical oncologists, radiologists, internal medicine and
primary care physicians, and fellows interested in the management
of gastrointestinal stromal tumors. Oncology nurses,
oncology physician assistants, and other individuals interested
in the treatment of cancer are also invited to attend.
|
CME Accreditation and Credit Designation
|
Physicians: Physicians’ Education
Resource is accredited by the Accreditation Council for Continuing
Medical Education to provide continuing medical education for
physicians.
Physicians’ Education Resource designates this educational
activity for a maximum of 2 AMA PRA Category 1
Credits™. Physicians should only claim credit commensurate
with the extent of their participation in the activity.
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP,
and AMA Category 1 CME credit for the PRA from organizations accredited by the ACCME.
|
Learning Objectives
|
At the conclusion of this symposium, you should be able to:
-
Diagnose GIST in patients based on the
tumor histology and the mutational status of c-Kit and PDGFR-α
-
Decide when to use targeted kinase therapy for adjuvant and/or
neoadjuvant treatment of localized GIST
based on evidence from clinical trials
-
Determine the optimal multimodality approach for localized
GIST, including surgical options, standard imaging
strategy (CT, MRI, FDG-PET), and/or perioperative use of
multitargeted kinase inhibitors
-
Assess the efficacy and safety of multitargeted kinase
inhibitors in advanced/metastatic GIST, including
choosing the optimal dose, duration, and sequence of
therapy based on evidence from clinical trials
-
Evaluate the efficacy and safety of novel inhibitors,
such as mTOR, Src kinase, and HSP90 inhibitors, in
the
treatment of advanced GIST
-
Discuss the standard criteria, such as tumor shrinkage
and decreased density, used to measure tumor response to therapy based on imaging techniques,
including CT, MRI, and FDG-PET
|
Acknowledgement
|
Supported by an educational grant from
|
| |
|
| |
|